Background: The maintenance of the body's Mg 2+ balance is of great importance because of its involvement in numerous enzymatic systems and its intervention in neuromuscular excitability, protein synthesis, and nucleic acid stability. Recently, the transient receptor potential melastatin 6 (TRPM6) was identified as the gatekeeper of active Mg 2+ transport and therefore plays a crucial role in the regulation of Mg
Introduction
The maintenance of the body's Mg 2+ balance is of crucial importance for various vital cellular processes [1, 2] . Mg 2+ homeostasis in mammals depends on the equilibrium between intestinal absorption and renal excretion. The renal distal convoluted tubule (DCT) reabsorbs w10% of the filtered Mg 2+ , and the reabsorption rate in this segment defines the final urinary Mg 2+ concentration [3] . Mg 2+ reabsorption in DCT is active and transcellular in nature, but the molecular details and regulation of this pathway remain largely unknown. Recently, transient receptor potential melastatin 6 (TRPM6) was identified as a pivotal component in active Mg 2+ (re)absorption, mutations of which cause hypomagnesemia with secondary hypocalcemia (HSH) [4, 5] . TRPM6 is localized along the apical membrane of DCT and intestinal cells. It confines a Mg 2+ -permeable channel, the activity of which is strongly regulated by the intracellular Mg 2+ concentration ([Mg 2+ ] i ) [2] . Expression of TRPM6 is regulated by dietary Mg 2+ , whereas TRPM7 is unaffected, supporting the idea of an important role of TRPM6 in transepithelial Mg 2+ transport [6] . Remarkably, TRPM6 and TRPM7 contain a unique carboxyl (C)-terminal serine/threonine protein kinase domain belonging to the a-kinase family [7] [8] [9] . This distinctive combination of a channel and an enzyme domain within a single molecule raises still unsolved questions concerning the regulatory role of this catalytic domain on channel activity. While it has been demonstrated that the TRPM7 a-kinase is able to autophosphorylate the channel and downstream substrates such as myosin IIA heavy chain and annexin I [10] [11] [12] [13] , the role of this a-kinase activity in modulating channel function is far from clear. Previous studies indicated that the a-kinase activity is not essential for TRPM7 activation [11, 13] and that regulation of TRPM7 activity by intracellular Mg 2+ is dissociated from autophosphorylation or a-kinase activity [13] . Other groups demonstrated regulation of TRPM7 activity by intracellular Mg 2+ and nucleotides as well as the cAMP/protein kinase A pathway, which required the a-kinase [14, 15] . It was reported that deletion of the TRPM7 a-kinase domain or phosphotransferase-deficient kinase mutants results in nonfunctional channels [7] . Compared to TRPM7, little is known about the a-kinase function of TRPM6. So far, only one study reported that the a-kinase of TRPM6 is capable of crossphosphorylation of TRPM7, but not vice versa, underlying the functional nonredundancy of these two ''chanzymes'' [12] .
The aim of the present study was, therefore, to investigate the role of the a-kinase domain in TRPM6 channel activity through the identification of regulatory proteins specifically interacting with the a-kinase domain.
Results

RACK1 Associates with TRPM6
To identify potential TRPM6-interacting proteins, two independent approaches were used, i.e., the yeast two-hybrid screening of a mouse kidney cDNA library with the complete C-tail of TRPM6 and the combination of a GST pull-down with the a-kinase domain of TRPM6 in mouse kidney lysate followed by Fourier transform ion cyclotron resonance mass spectrometry (FTMS). RACK1, a scaffold protein originally discovered as an adaptor for protein kinase C (PKC) [16] , was identified as a TRPM6 interacting protein in both approaches. Figure 1A shows that RACK1 interacted with TRPM6, whereas no interaction was observed in the absence of either RACK1 or the TRPM6 C-tail. To further establish this interaction, GST pull-down binding assays were performed, which demonstrated that RACK1 interacts specifically with the a-kinase domain, but not with GST alone ( Figure 1B) . Next, the association between TRPM6 and RACK1 was substantiated in mammalian HEK293 cells. RACK1 coprecipitated with the GST-kinase and GST-TRPM6-C-tail, but not with GST-TRPM6-C-tail-D-kinase and GST alone ( Figure 1C ). Furthermore, coprecipitation experiments also demonstrated that the endogenously expressed RACK1 in HEK293 cells is associated with the TRPM6 a-kinase domain ( Figure 1D ). Finally, coimmunoprecipitation studies of RACK1 with full-length TRPM6 or TRPM6 D-kinase in HEK293 cells showed that wild-type TRPM6 but not TRPM6 D-kinase coprecipitates with RACK1 ( Figure 1E ).
Mapping of the RACK1 Binding Site in TRPM6
To determine the RACK1 binding site within TRPM6, a series of deletion mutants in the a-kinase domain of the channel was constructed and evaluated for their interaction with [ 35 S]-methionine-labeled RACK1 protein using pull-down experiments ( Figure 1F ). The interaction between the two proteins was abolished when TRPM6 was truncated at position 1857, whereas truncation at position 1885 had no effect on the interaction with RACK1. Moreover, a GST-fusion protein containing only the short stretch between the amino acids 1857 and 1885 of the TRPM6-kinase domain bound to RACK1 ( Figure 1F ). Therefore, the RACK1 binding site within TRPM6 is restricted to the region between the positions 1857 and 1885. The integrity and quantity of the GST-fusion proteins was analyzed and confirmed by Coomassie staining ( Figure 1G ). To explore the RACK1 binding site in the TRPM6 a-kinase domain, the tertiary structure of TRPM6 a-kinase domain was modeled by SWISS-MODEL (http://swissmodel.expasy.org// SWISS-MODEL.html) ( Figure 1H ), based on the homology between the TRPM6 a-kinase and the crystallized TRPM7 a-kinase domain [17] . Due to the high homology between the TRPM7 and TRPM6 a-kinase domains (84%), these two a-kinases share a highly conserved secondary structure. Indeed, the GST pull-down assay showed that RACK1 also interacts with the TRPM7 a-kinase domain (see Figure S1A available online). The surface and accessibility analysis of the RACK1 binding site (6th, 7th, and 8th b sheets) suggested that, among the 28 amino acids of the RACK1 binding site, 18 are localized at the surface of the TRPM6 a-kinase domain (see http://www. cmbi.ru.nl/whvensela/trpm6/).
RACK1 and TRPM6 Coexpress in Kidney
To study the localization of RACK1 in kidney, immunohistochemistry was performed on kidney sections using the thiazide-sensitive Na + /Cl 2 cotransporter (NCC) as a DCT marker. These analyses indicated immunopositive staining for RACK1 in the NCC-expressing DCT cells (Figure 2A 
RACK1 Inhibits TRPM6 Channel Activity
The functional role of RACK1 on TRPM6 current was investigated in HEK293 cells by whole-cell recordings. In mocktransfected HEK293 cells, dialyzed with a Mg 2+ -free pipette solution, around 40% of the cells developed small albeit significant currents, generally referred to as the Mg 2+ -inhibited cation current (MIC current) [18, 19] . This endogenous current was approximately ten times smaller and developed over a longer time period compared to the TRPM6 current ( Figure S1D ). We demonstrated that coexpression of RACK1 with TRPM6 significantly inhibited the TRPM6-mediated current amplitude in a dose-dependent manner. TRPM6 current was reduced by 56% 6 4% and 88% 6 3% compared to TRPM6 alone when 0.1 mg or 0.5 mg RACK1 cDNA, respectively, was cotransfected ( Figures 3A-3C and Figure S2A ). Furthermore, RACK1 also inhibited the TRPM7 channel activity (Figures S1B and S1C). However, the inhibitory effect of RACK1 on TRPM6/7 current was specific, since RACK1 did not significantly affect the current in TRPV5-expressing HEK293 cells (211% 6 3%, 216% 6 3%, and 29% 6 2% at 280 mV in divalent-free, EDTA, and 10 mM Ca 2+ solutions, respectively, n = 10-12 cells as described previously [20] ). Importantly, RACK1 coexpression with an a-kinase-deleted TRPM6 mutant (TRPM6 D-kinase) failed to suppress the TRPM6 D-kinase-mediated current at both +80 and 280 mV ( Figures 3D and 3E and Figure S2B ). Small Interference RNA-Mediated RACK1 Silencing Stimulates TRPM6 Activity To further elucidate the molecular mechanism of the RACK1 inhibitory effect, siRNA technology was applied. Immunoblot analysis revealed a significant downregulation of RACK1 protein abundance in HEK293 cells expressing RACK1-targeted siRNA(1) and siRNA (2) in comparison to mock-transfected cells ( Figures 3F and 3G ). siRNA(1) and siRNA(2) for RACK1 induced a significant increase of the TRPM6 current amplitude [356 6 31 pA/pF, 218 6 1 pA/pF and 397 6 25 pA/pF, 233 6 6 pA/pF for RACK1 siRNA(1) and siRNA(2) at +80 and 280 mV, respectively, in comparison to 275 6 26 pA/pF, 213 6 2 pA/pF for TRPM6 and empty vector, respectively] ( Figure 3H and Figures  S2C and S2D ). The siRNA for luciferase, siRNA(luc), did not significantly affect TRPM6 current amplitudes. Importantly, RACK1 siRNA(1), RACK1 siRNA(2), and siRNA(luc) did not alter the current amplitude of the TRPM6 D-kinase mutant ( Figure 3I and Figures S2E and S2F ).
RACK1-Mediated Inhibition of TRPM6 Is Kinase Activity Dependent
Next, the role of the kinase-mediated autophosphorylation was investigated. TRPM6 a-kinase autophosphorylation activity was first assessed by an in vitro protein kinase assay. Figure 4A indicates that TRPM6 is autophosphorylated, whereas deletion of its a-kinase or the addition of alkaline phosphatase prevents channel autophosphorylation. Next, we constructed a phosphotransferase-deficient mutant (K 1804 R) according to the homologous TRPM7 phosphotransferase-deficient mutant (K 1648 R) [11] . The in vitro phosphorylation assay showed that the kinase activity of the K 1804 R mutant was abolished, while the mutant was equally expressed compared to wild-type TRPM6 ( Figure 4B ). K 1804 R mutant was still able to bind RACK1, as demonstrated by GST pulldown assay ( Figure S3A ). K 1804 R mutant displayed current amplitude and current development similar to the wild-type channel. Importantly, RACK1 was unable to inhibit the K 1804 R mutant-mediated current ( Figure 4C and Figures S3B and S3C).
Autophosphorylation of Threonine 1851 in the Kinase Domain Is Essential for the Inhibitory Effect of RACK1
To address the autophosphorylation site(s) in TRPM6 that are essential for the regulatory effect of RACK1, the purified GST-TRPM6 a-kinase protein was subjected to an in vitro phosphorylation assay and subsequently analyzed by FTMS. A mutation prevented the inhibitory effect of RACK1 ( Figure 5D and Figures S4C and S4D) , whereas the RACK1-induced inhibition remained unaltered when coexpressed with the T 1851 D mutant ( Figure 5E and Figures S4E and S4F) . ] on TRPM6 and T
1851
A mutant autophosphorylation was investigated. TRPM6 autophosphorylation activity was strongly dependent on the Mg 2+ concentration and steadily increased in the physiological range of 0.1-1.0 mM Mg 2+ ( Figure 5F ). In contrast, the autophosphorylation activity of the T 1851 A mutant was not affected by the Mg 2+ concentration ( Figure 5G ). Both TRPM6 and T
A mutant channel activities were significantly inhibited by Mg 2+ in the patchpipette. However, the T 1851 A mutant channel was less sensitive to the intracellular Mg 2+ concentration compared to wild-type TRPM6 (IC 50 0.72 6 0.07 mM versus IC 50 0.51 6 0.06 mM, respectively) ( Figure 5H ). Figure 5I showed that knockdown of endogenous RACK1 by siRNA significantly reduces the Mg 2+ -dependent inhibition of the TRPM6 current. Together, these data suggest that the T 1851 phosphorylation-dependent inhibitory effect of RACK1 may play an important role in the suppression of the TRPM6 current by intracellular free Mg 2+ .
Coexpression of RACK1 Does Not Affect Expression of TRPM6 at the Plasma Membrane The influence of RACK1 on the amount of TRPM6 channels expressed at the plasma membrane was investigated by cell-surface biotinylation experiments. As shown in Figure 6 (upper panel), coexpression of RACK1 did not affect the amount of TRPM6 channels expressed at the plasma membrane. Of note, TRPM6 was equally expressed in all tested conditions, as determined in the total cell lysates ( Figure 6 , bottom panel).
RACK1 Inhibits TRPM6 in a PKC-Dependent Manner
Next, the effect of PKC activation by phorbol 12-myristate 13-acetate-PMA (PMA) [21] on the regulatory effect of RACK1 was studied. PKC activation by preincubation with 100 nM PMA for 5 min prevented the inhibitory effect of RACK1 on the TRPM6 current ( Figure 7B and Figures S5C  and S5D ). The current amplitude in the presence of PMA was, however, not modified in cells expressing TRPM6 only ( Figure 7A and Figures S5A and S5B) . To confirm the specificity of PMA, HEK293 cells coexpressing TRPM6 and RACK1 were incubated with 5 mM chelerythrine chloride, a specific PKC inhibitor [22] , for 20 min prior to PMA treatment. As shown in Figure 7B and Figures S5C and S5D , the stimulatory action of PMA was counteracted by chelerythrine chloride, suggesting that the PMA effect is indeed due to PKC activation. To further elucidate the PKC effect, the TRPM6 C-tail was coexpressed with RACK1 in HEK293 cells, subjected to PKC activation by PMA or vehicle, and subsequently precipitated using glutathione Sepharose 4B beads. The interaction of RACK1 with the TRPM6 C-tail was significantly reduced when PKC was activated ( Figure 7C, upper panel) . Importantly, RACK1 was equally expressed in all situations ( Figure 7C , lower panel).
Discussion
In the present study, we identified RACK1 as the first TRPM6-associated protein and demonstrated that RACK1 inhibits TRPM6 channel activity depending on the phosphorylation state T 1851 in the a-kinase domain. First, RACK1 binds to the TRPM6 a-kinase domain and shares a similar expression pattern with TRPM6 in the kidney. Second, overexpression of RACK1 inhibits TRPM6 activity, and conversely, silencing of RACK1 by siRNA increases the TRPM6 current. Third, the RACK1-mediated inhibition of TRPM6 is prevented by deletion of the a-kinase domain. Fourth, inactivation of the a-kinase abrogates the inhibitory effect of RACK1. Fifth, T 1851 is identified as an important autophosphorylation site in TRPM6-modulating channel activity by RACK1. Sixth, T 1851 was crucial for the Mg 2+ sensitivity of TRPM6 autophosphorylation and channel activity. Finally, knockdown of endogenous RACK1 by siRNA significantly reduces the Mg 2+ -dependent inhibition of the TRPM6 current.
TRPM6 forms the Mg 2+ influx channel involved in intestinal and renal Mg 2+ (re)absorption and is so far the only known molecular identity in the process of active transepithelial 
Mg
2+ transport. However, TRPM6 regulation remains poorly understood. In this respect, the identification of RACK1 as a TRPM6 regulator provides the first molecular insight into the control of renal Mg 2+ entry and, therefore, into the maintenance of Mg 2+ balance. The interaction between RACK1 and TRPM6 was confirmed by GST pull-down assay and coimmunoprecipitation. Unfortunately, similar studies investigating an interaction between endogenous TRPM6 and RACK1 in kidney DCT cells were unsuccessful, possibly due to the low protein abundance of the channel. In addition, we demonstrated that endogenously expressed RACK1 in HEK293 cells interacts with the TRPM6 a-kinase domain. At the molecular level, our results suggest that RACK1 specifically binds to the 6th, 7th, and 8th b sheets of the a-kinase domain. Eighteen amino acids of the RACK1 binding site are located on the peripheral region of the tertiary structure of the TRPM6 a-kinase domain, which may facilitate the association between RACK1 and TRPM6.
Importantly, we showed that RACK1 is abundantly present in TRPM6-expressing tubules, which further suggests the physiological relevance of the interaction between these proteins in the kidney.
RACK1, a member of the WD-40 family of proteins, is regarded as a scaffolding protein in multiple intracellular signal transduction pathways, including ion channel proteins such as the IP 3 receptor, NMDA receptor, and GABA A receptor channels [23] [24] [25] . RACK1-mediated decline of the TRPM6 current was dose dependent, and depletion of endogenously expressed RACK1 in HEK293 cells resulted in increased TRPM6 currents. The inhibitory effect of RACK1 requires the a-kinase domain with functional phosphotransferase activity. This was supported by the analysis of the TRPM6 D-kinase and the phosphotransferase-deficient (K 1804 R) mutants, which were both insensitive to RACK1. While the autophosphorylation activity of the a-kinase domain has been well documented [ [10] [11] [12] [13] , the regulatory role of this catalytic domain on channel activity remains elusive. Previously, it has been demonstrated that the balance between phosphorylation and dephosphorylation operates as a key mechanism to regulate ion channel activity [26, 27] . However, the phosphotransferase-deficient K 1804 R mutant displayed currents indistinguishable from wild-type TRPM6. Interestingly, the mutants T 1851 A and T 1851 D displayed currents similar to the wild-type channel but exhibited a significant albeit reduced autophosphorylation, while the autophosphorylation of mutant K 1804 R was fully abolished. These data suggest that, besides T 1851 , additional autophosphorylation sites are present in TRPM6. Our findings support the conclusion that TRPM6 a-kinase autophosphorylation events are not vital for TRPM6 channel activation. Consistently, previous studies showed that TRPM7 phosphotransferase activity is not essential for channel activation [12, 13] . In contrast, the inhibitory action of RACK1 requires functional phosphotransferase activity. This notion is supported by the fact that the current of the phosphorylation-impaired mutants (K 1804 R and T
1851
A) is insensitive to RACK1. Furthermore, the constitutive phosphorylated mutant T 1851 D was still inhibited by RACK1. Based on these observations, an increased channel activity for the phosphorylation-impaired mutants (K 1804 R and T 1851 A) and the TRPM6 D-kinase mutant was expected. However, functional analysis of these mutated channel proteins did not indicate elevated channel activity. It has been demonstrated that the a-kinase domain can regulate TRPM7 channel activity via other signaling pathways besides RACK1. For instance, previous studies [11, 14, 15] indicated that the TRPM7 activity controlled by intracellular Mg 2+ , nucleotides, and the cAMP/protein kinase A pathway requires the a-kinase domain or kinase activity. Therefore, it is conceivable that removing the a-kinase domain or suppressing its phosphotransferase activity may abolish associated regulation(s) of TRPM6 channel activity. This could compensate a potential upregulation of TRPM6 activity caused by removal of the inhibitory RACK1 action. In reminiscence of the adjacent location of the autophosphorylation site in the a-kinase and the RACK1 binding site, we hypothesize that the phosphorylation state of T 1851 plays a key role in controlling channel activity via RACK1. Together, our results convincingly demonstrate a novel indirect model of regulation in which RACK1 functions as a mediator linking autophosphorylation of the a-kinase domain to channel activity. In this way, TRPM6 channel activity is controlled efficiently to manage constitutively active epithelial Mg 2+ channels. Furthermore, cell-surface biotinylation experiments demonstrated that coexpression of RACK1 does not affect the amount of TRPM6 channels expressed at the plasma membrane. These data suggest that the inhibitory effect of RACK1 on TRPM6 is likely due to channel gating. Association of RACK1 and TRPM6 seems a dynamic process that can be abolished by PKC activation, thereby preventing the inhibitory effect of RACK1. An increased TRPM6 current upon PMA treatment in TRPM6-overexpressed HEK293 cells was anticipated, since PKC activation prevents the RACK1 inhibitory effect in TRPM6 and RACK1-overexpressing HEK293 cells. However, this inhibitory effect was not observed, which might be due to the fact that the amount of endogenous RACK1 is insufficient to inhibit the overexpressed TRPM6.
TRPM6 and TRPM7 confine a Mg 2+ -permeable channel of which the activity is strongly regulated by [Mg 2+ ] i [2, 7, 13, 14, 28] ] i is disassociated from its a-kinase activity [13] , whereas other studies suggested the involvement of the a-kinase domain [11, 14] . In our study, the T 1851 A mutant is less sensitive to [Mg 2+ ] i , which is in agreement with previous studies showing that TRPM7 phosphotransferase activity influences the Mg 2+ -dependent inhibition of channel activity [11, 14] [11, 32, 33] . Moreover, we showed that siRNA-mediated downregulation of endogenous RACK1 significantly reduced the inhibition of the TRPM6 current by Mg 2+ . These findings suggest that RACK1 is involved in the Mg 2+ sensitivity of TRPM6 channel activity. Together, we suggest that TRPM6-mediated Mg 2+ influx induces phosphorylation of T 1851 located in the a-kinase domain. Subsequently, the phosphorylation of T 1851 will activate the inhibitory effect of RACK1. This latter step may act as an intracellular feedback regulation to control TRPM6-mediated Mg 2+ influx and avoid Mg 2+ overload during renal epithelial Mg 2+ transport. Our data contribute to a further understanding of molecular mechanisms involved in renal Mg 2+ handling and to the a-kinasedependent regulation of TRPM6 channel activity.
Experimental Procedures
Cell Culture and Transfection HEK293 cells were grown and transfected as described previously [34] .
DNA Constructs and cRNA Synthesis
Information about the TRPM6 and RACK1 constructs used is available on-line.
Yeast Two-Hybrid System Yeast two-hybrid experiments were performed as previously described [35] .
GST-Fusion Proteins and Pull-Down Assay TRPM6 a-kinase GST fusion protein was purified as previously described [35] . Please see Supplemental Data for detailed information.
Electrophysiology
Whole-cell recordings with standard pipette and extracellular solutions were performed as already described [34] . The information on pipette solutions used for the intracellular Mg 2+ experiments is available online.
Coprecipitation, Coimmunoprecipitation, and Immunoblotting
The supernatants of cell lysates were incubated overnight with glutathione Sepharose 4B beads at 4 C. The anti-RACK1 antibody (IgM) was labeled with biotin and precipitated by neutravidin-agarose beads (Pierce) and then incubated overnight with the supernatants of the lysates. After extensive washing with lysis buffer, the bound proteins were eluted and subjected to SDS-PAGE followed by western blotting analysis. The immunoblotting experiments were performed as previously described [35] . Please see Supplemental Data for detailed information.
In Vitro Phosphorylation and Phosphatase Assays
The precipitated TRPM6 was incubated in kinase reaction buffer and 2 mCi of [g C. For the in vitro phosphatase assay, 15 units alkaline phosphatase (Roche, Mannheim, Germany) were added to TRPM6 immunoprecipitates before in vitro phosphorylation assays. The reaction was terminated by three washing steps with phosphorylation washing buffer. Phosphorylation was analyzed after gel electrophoresis by autoradiography. Please see Supplemental Data for detailed information.
Statistical Analysis
Please see Supplemental Data for detailed information.
Supplemental Data
Additional information about the Experimental Procedures and five figures, can be found online at http://www.current-biology.com/cgi/content/full/ 18/3/168/DC1/.
